The DTWD2 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population of human B lymphocytes designed for loss-of-function interrogation of the DTWD2 gene. Originating from the Raji B-cell line, this product enables detailed investigation of DTWD2’s role in tRNA modification and translational control. The polyclonal format offers a genetically diverse yet enriched model of DTWD2 deficiency, suitable for comprehensive functional analyses in B-cell biology.
The Raji cell line is an Epstein-Barr virus (EBV)-positive, suspension-adapted human Burkitt’s lymphoma-derived B lymphocyte line. These cells maintain hallmarks of B-cell physiology, including antibody production, antigen presentation, and robust immune signaling. Their transformed phenotype and rapid proliferation make them a widely used model for studying B-cell malignancies, oncogenic mechanisms, and therapeutic intervention.
DTWD2 is a predicted tRNA wybutosine-synthesizing enzyme, homologous to yeast enzymes that catalyze the conversion of guanosine to wybutosine at position 37 of tRNAPhe??a critical modification for correct codon-anticodon pairing and translational fidelity. It operates within the tRNA wybutosine biosynthesis pathway, interacting with catalytic partners such as TRMT5, TYW1, TYW2, TYW3, and TYW4, as well as ribosomal proteins to influence global translation. Upstream regulation may involve transcription factors MYC and SP1, both frequently activated in B-cell cancers. Loss of DTWD2 can compromise tRNA maturation, leading to defective ribosome function and aberrant protein synthesis, ultimately impacting cell proliferation and viability.
In Raji lymphoma cells, DTWD2 knockout provides a powerful model to explore the intersection of tRNA modification and B-cell oncogenesis. MYC-driven translational programs essential for sustained proliferation may rely on proper wybutosine synthesis, positioning DTWD2 disruption as a means to uncover translational vulnerabilities in lymphoma. The polyclonal population preserves the natural variability of the knockout response, enabling studies of heterogeneous effects on cell cycle progression, apoptosis, and signaling pathways within a disease-relevant context.
This knockout population supports a breadth of applications, including quantitative analysis of tRNA modification by LC-MS, assessment of protein expression changes via western blotting, and RT-qPCR for transcriptional responses. Functional assays such as proliferation and viability measurements, flow cytometry-based cell cycle and apoptosis profiling, and ribosome profiling to evaluate translational efficiency are readily performed. The polyclonal nature is ideal for pooled screens, dose-response studies, and therapeutic target validation. For additional details and ordering information, please contact Ascent Research.
